OliPass Corp
KOSDAQ:244460
OliPass Corp
OliPass Corp. develops biological products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2019-09-20. The firm principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.
OliPass Corp. develops biological products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2019-09-20. The firm principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.